NEW YORK, Feb. 21, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of FXCM, Inc. (NASDAQ:FXCM) between March 15, 2012 and February 6, 2017.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) from September 4, 2009 through at least 2014, FXCM’s U.S. subsidiary engaged in false and misleading solicitations of its retail foreign exchange customers by concealing its relationship with its most important market maker and by misrepresenting that its “No Dealing Desk” platform had no conflicts of interest with its customers; (2) FXCM’s U.S. subsidiary made false statements to the National Futures Association about its relationship with the market maker; and (3) as a result, Defendants’ statements about FXCM’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in FXCM you have until April 10, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


FDA Approves Mitapivat for Anemia in Thalassemia Patients
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 



